GlassScriptPhysician profile
Sonal Chaudhry
NPI 1992875355
$3,570.33
in general payments reported to CMS, 2019-2025
30 companies · $358 in 2025
The $358 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $263 · 2021: $454 · 2022: $897 · 2023: $771 · 2024: $263 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,392.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $437.39 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $427.51 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $367.67 | 2019-2025 | Synthroid |
| Lilly USA, LLC | $335.59 | 2021-2024 | Jardiance, Zepbound, Mounjaro |
| Horizon Therapeutics Plc | $228.12 | 2021-2023 | Tepezza |
| Abbott Laboratories | $223.11 | 2021-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $168.37 | 2021-2025 | Afrezza |
| Amneal Pharmaceuticals LLC | $153.64 | 2021-2023 | Unithroid |
| Amgen INC. | $138.95 | 2019-2025 | Evenity, Prolia |
| Syndax Pharmaceuticals, INC. | $135.15 | 2025 | |
| Sanofi-Aventis U.S. LLC | $122.07 | 2020-2023 | |
| Currax Pharmaceuticals LLC | $120.64 | 2022-2025 | Contrave, Nexletol, Nexlizet |
| Depuy Synthes Sales INC. | $99.72 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.88 | 2022-2023 | |
| Janssen Biotech, INC. | $79.24 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $69.64 | 2023 | Korlym |
| Xeris Pharmaceuticals, INC. | $59.26 | 2022 | |
| Intra-Sana Laboratories | $53.71 | 2023 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Radius Health, INC. | $34.95 | 2023-2024 | Tymlos |
| Insulet Corporation | $30.53 | 2022 | |
| Pfizer INC. | $27.58 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.84 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.62 | 2020 | |
| Boston Scientific Corporation | $19.02 | 2024 | |
| Eusa Pharma (US) LLC | $18.55 | 2022 | |
| Recordati_rare_diseases_inc. | $18.55 | 2022 | |
| Evofem Biosciences, INC. | $17.72 | 2022 | |
| Antares Pharma, INC. | $15.81 | 2024 | Xyosted |
| Vistapharm, INC. | $15.00 | 2021 | |
| Grt US Holding, INC. | $11.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonal Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.